

## REFLUXAN

CE 0373

Suspension for the treatment of gastroesophageal reflux disease with HMW mucopolysaccharides providing a barrier effect.

### ***Gluten-free formulation***

### ***Natural lactose-free formulation***

### **Indications**

REFLUXAN is an oral medical device with mechanical action, used to treat gastroesophageal reflux disease. It is indicated in cases of gastric pyrosis, oesophagitis, dysphonia, irritative cough, and regurgitation caused by gastric reflux in adults and children over 12 years.

### **Composition**

Sodium alginate, HMW mucopolysaccharides, potassium bicarbonate, calcium carbonate, sodium bicarbonate, water, xylitol, xanthan gum, sodium hydrate, carbomer, potato protein extract, aroma, sucralose, chlorhexidine digluconate, hexamidine

### **Pack**

20 sachets, each with 15 ml of the suspension

### **Use**

One single dose of 15 ml after main meals and before going to bed or according to your doctor's advice. Shake well before use.

### **Warnings**

The recommended dose should not be exceeded, please follow the instructions for use. Do not dissolve in water. Do not use in cases of known or suspected hypersensitivity to one or more of the product ingredients. If you develop any side effects, please stop the treatment and talk with your doctor.

Keep out of the reach of children.

Store in a cool and dry place, away from any heat sources. Do not freeze.

Do not use after the expiry date. The shelf-life information refers to the product in undamaged and adequately stored package.

The product can be more or less viscous without any quality changes.

Sodium calls for special attention when giving alginate to persons affected with hypertension or heart or kidney failure.

The product may affect absorption of the oral medicines. Before use, you are advised to talk to your doctor if you are on a long-term treatment with other medicines or on a salt-restricted (sodium-restricted) diet, for example in cases of hypertension, heart problems or liver and kidney conditions,

and in cases of hyperglycaemia, nephrocalcinosis, and recurrence of kidney stones containing calcium.

Marketing Authorisation: 515-02-02013-21-005

This leaflet was approved: 17 August 2021



Officina Farmaceutica Italiana S.p.A., Via Verga, 14-24127, Bergamo Italia

Authorised representative:

**G Galenika**

Galenika a.d. Beograd, 11080 Belgrade, Batajnički drum b.b., Serbia

Holder of registration in the Register of Medical Devices in Montenegro:

GLK pharma d.o.o., Svetozara Markovića 46, 81000 Podgorica, Montenegro

Number and date of Marketing Authorisation: 2070/21/653-4405 of 29 September 2021

Marketing Authorisation Holder for BiH:

Galenika d.o.o., Vidovdanska b.b., 78 000 Banja Luka, BiH

Number and date of Marketing Authorisation: 06-07.4-1-6482-1/21 of 30 July 2021